(Rac) -Minzasolmin

(Rac) -Minzasolmin ((Rac) -UCB0599; NPT200-11) is a blood-brain barrier penetrated alpha-synuclein (ASYN) misfolding inhibitor. (Rac) -Minzasolmin acts on the early stage of ASYN aggregation process, by replacing the membrane-bound oligomers ASYN, allowing them to revert to the monomeric form, while preventing pathological aggregation. (Rac) -Minzasolmin effectively improves the ASYN deposition in the retina and the neuro-pathological indicators in two α-synuclein transgenic mouse models. (Rac) -Minzasolmin can be used for the studies of Parkinson's disease (PD) and dementia with Lewy bodies (DLB) [1].

Product Specifications

CAS Number

[1802518-63-3]

Product Name Alternative

(Rac) -UCB0599; NPT200-11

UNSPSC

12352005

Target

α-synuclein

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/rac-minzasolmin.html

Purity

99.87

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C1=CN=C(N2CCN(CC2)C)S1)NC(CCCC)CC3=CNC4=CC=CC=C34

Molecular Formula

C23H31N5OS

Molecular Weight

425.59

References & Citations

[1]Price DL, et al. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease. Sci Rep. 2018 Nov 1;8 (1) :16165.